NERRE THERAPEUTICS
NeRRe Therapeutics Ltd. operates as a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. The company was founded in 2012 and is based in Stevenage, United Kingdom.
NERRE THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2012-01-01
Address:
Stevenage, Herefordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.nerretherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
44 1438 906 960
Email Addresses:
[email protected]
Total Funding:
74.57 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Columbus Venture Partners
Columbus Venture Partners investment in Series B - NeRRe Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series B - NeRRe Therapeutics
Advent Life Sciences
Advent Life Sciences investment in Series B - NeRRe Therapeutics
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series B - NeRRe Therapeutics
OrbiMed
OrbiMed investment in Series B - NeRRe Therapeutics
The Future Fund
The Future Fund investment in Series B - NeRRe Therapeutics
Novo Holdings
Novo Holdings investment in Series B - NeRRe Therapeutics
Advent Life Sciences
Advent Life Sciences investment in Series B - NeRRe Therapeutics
OrbiMed
OrbiMed investment in Series B - NeRRe Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series B - NeRRe Therapeutics
Official Site Inspections
http://www.nerretherapeutics.com Semrush global rank: 3.33 M Semrush visits lastest month: 4.81 K
- Host name: 159.133.153.160.host.secureserver.net
- IP address: 160.153.133.159
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "NeRRe Therapeutics"
NeRRe Therapeutics – Home
May 31, 2023 · NeRRe Therapeutics is led by CEO Mary Kerr and an experienced management team who sold a sister NK antagonist company KaNDy Therapeutics to Bayer in 2020 for …See details»
About Us - NeRRe Therapeutics
NeRRe Therapeutics is a clinical-stage company developing the neurokinin (NK)-1 receptor antagonist orvepitant for the treatment of common, chronic, and debilitating conditions caused …See details»
Our People - NeRRe Therapeutics
Steve Pawsey joined NeRRe Therapeutics as Chief Medical Officer in January 2017. An anaesthetist by training… Susan has 18 years’ experience in the pharmaceutical industry, working within Clinical Operations and Clinical …See details»
NeRRe Therapeutics Ltd - LinkedIn
Developing a breakthrough treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis. NeRRe Therapeutics is developing orvepitant, a neurokinin (NK)-1 receptor...See details»
NeRRe Therapeutics - Crunchbase Company Profile
View contacts for NeRRe Therapeutics to access new leads and connect with decision-makers. NeRRe Therapeutics Ltd. operates as a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. The …See details»
NeRRe | Advent Life Sciences
NeRRe Therapeutics is a clinical-stage company developing orvepitant, a neurokinin (NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders.See details»
NeRRe Therapeutics | Advent Life Sciences
About NeRRe Therapeutics (www.nerretherapeutics.com) NeRRe Therapeutics is a clinical-stage company developing orvepitant, a neurokinin(NK)-1 receptor antagonist, as a first in class, …See details»
NeRRe Therapeutics - PitchBook
Developer of clinical neurotoxin receptor antagonists designed to treat neuronal hypersensitivity.See details»
NeRRe Therapeutics - VentureRadar
Website: http://www.nerretherapeutics.com/ Develops neurokinin receptor antagonists for treating debilitating conditions caused by neuronal hypersensitivity, using a portfolio acquired from …See details»
Contact Us - NeRRe Therapeutics
NeRRe Therapeutics Limited (NeRRe) is a company incorporated under the laws of England and Wales and having its registered offices at Stevenage Bioscience Catalyst, Incubator Building, …See details»
NeRRe Therapeutics Company Profile - Office Locations ... - Craft
NeRRe Therapeutics is a clinical-stage company developing a pipeline of three neurokinin-1 antagonists for the treatment of common, chronic and debilitating conditions caused by …See details»
NERRE THERAPEUTICS LTD - Companies House
NERRE THERAPEUTICS LTD - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business …See details»
NeRRe Therapeutics - Overview, News & Similar companies
Feb 20, 2020 · View NeRRe Therapeutics (www.nerretherapeutics.com) location in Hertfordshire, United Kingdom , revenue, industry and description. Find related and similar companies as …See details»
NeRRe Therapeutics raises £20 million in a Series B2 financing round
Stevenage, UK, 7 July 2021 – NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for …See details»
NeRRe Therapeutics raises £20 million in a Series B2 financing round
Jul 7, 2021 · NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough …See details»
NeRRe Therapeutics Appoints Andrew Kay as Chairman of the Board
Sep 27, 2017 · NeRRe Therapeutics is a private UK based clinical-stage company developing a unique pipeline of three neurokinin (NK)-1 antagonists for the treatment of common, chronic …See details»
NeRRe Therapeutics raises £20 million in a Series B2
Stevenage, UK, 7 July 2021 – NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for …See details»
GSK spinout bags £23M to take NK antagonists into phase 2
Jan 5, 2017 · NeRRe Therapeutics has raised £23 million ($28 million) in a Series B backed by new investors Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed. The …See details»
Pipeline - NeRRe Therapeutics
If you are interested in talking to us about partnering any of our pipeline assets please contact us via email at: [email protected]. DISCOVER PARTNERING NeRRe Therapeutics is …See details»
News – NeRRe Therapeutics
Sep 29, 2019 · European Respiratory Society International Congress, Madrid 29 September 2019 Dr Steve Pawsey, CMO at NeRRe Therapeutics presents a poster at the European …See details»